Baxter International Inc vs Braze Inc — how do they compare? Baxter International Inc trades at $27.2 (market cap $14.27B), while Braze Inc trades at $27.64 (market cap $3.18B). The key difference: Baxter International Inc is far larger — about 4.5× Braze Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Braze Inc pays none. Which is the better fit depends on your goals.
| BAX | BRZE | |
|---|---|---|
Market Cap | $14.27B | $3.18B |
Sector | Health | Technology |
52-Week High | $28.35 | $36.19 |
52-Week Low | $15.80 | $15.79 |
Enterprise Value | $21.79B | $2.87B |
Dividend Yield | 0.14% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.09, down 2.48% today but showing strong technical momentum with bullish moving averages and recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations by 53%, and raised full-year guidance. Despite negative net margins and elevated P/E ratio of 87.85, improving operational performance and positive cash flow projections for 2026 suggest potential turnaround.
The stock presents a mixed outlook with strong technical momentum and recent operational improvements offset by valuation concerns and profitability challenges. Key opportunities include continued execution on raised guidance and debt reduction efforts, while risks center on margin pressure and high debt levels. Analyst consensus leans neutral with 55.55% hold ratings and $25.43 price target below current levels.
Braze (BRZE) trades at $27.50, down 4.35% today but showing strong technical momentum with bullish moving averages. The company demonstrates impressive revenue growth, reaching $593.41 million in 2025 with 30% year-over-year expansion, though profitability remains elusive with a -15.51% net margin. Recent news highlights insider selling but also strong AI-driven customer engagement demand and four consecutive quarters of organic revenue acceleration.
The outlook remains positive with 96% analyst buy ratings and a $34.78 consensus target suggesting 26% upside. Key risks include persistent unprofitability despite growth and competitive pressures in the customer engagement software space. The stock's trajectory depends on continued revenue acceleration and eventual path to profitability.
Trailing returns across standard periods
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →